- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Sa | Puma Biotechnology Q4 2025 slides: NERLYNX revenue rises 15% sequentially | ||
| Sa | BioCryst 2025 slides: path to $1B revenue, Navenibart expands portfolio | ||
| Sa | Blend Labs Q4 2025 slides: revenue beats, margins expand amid EPS miss | ||
| Sa | Bapcor 1H26 slides: new CEO outlines turnaround after $105M loss | ||
| Sa | Cheniere Q4 2025 slides: record LNG exports drive 42% cash flow surge | ||
| Sa | Fundrise Innovation Fund faces steep reversal after explosive NYSE debut | ||
| Sa | KPMG UK moves to slash audit headcount as attrition rates plummet - Bloomberg | ||
| Sa | Cathie Wood's ARK sells Nvidia stock, buys Arcturus Therapeutics | ||
| Sa | Constellation Software founder Mark Leonard to step down from board | ||
| Sa | Lantern Pharma denies CEO departure claim, calls report false | ||
| Sa | Goldman Sachs upgrades Nokia stock rating on AI infrastructure growth | ||
| Fr | TD Cowen cuts Tilray stock price target on aluminum cost pressures | ||
| Fr | BMO Capital raises Legence stock price target on growth outlook | ||
| Fr | Morgan Stanley reiterates Camden Property Trust stock rating after leadership changes | ||
| Fr | William Blair reiterates Autolus stock rating on commercial execution focus | ||
| Fr | NextPlat approves 1-for-10 reverse stock split effective April 6 | ||
| Fr | Physical Intelligence in talks for funding at $11 billion valuation - Bloomberg | ||
| Fr | Leerink reiterates Monopar stock rating on Wilson disease drug potential | ||
| Fr | Truist reiterates OmniAb stock Buy rating on biotech recovery | ||
| Fr | Main Street Capital prices $200M notes offering at premium | ||
| Fr | InMed receives Nasdaq minimum bid price deficiency notice | ||
| Fr | Leerink raises AstraZeneca stock price target to $220 on COPD drug data | ||
| Fr | Raymond James reiterates Monopar stock rating on NDA timing shift | ||
| Fr | Keurig Dr Pepper completes JDE Peet's takeover with 96% acceptance | ||
| Fr | BofA raises Rocket Pharmaceuticals price target on execution view |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.